CN109550027A - 一种改善睡眠质量的口服液的制备方法 - Google Patents
一种改善睡眠质量的口服液的制备方法 Download PDFInfo
- Publication number
- CN109550027A CN109550027A CN201910116368.7A CN201910116368A CN109550027A CN 109550027 A CN109550027 A CN 109550027A CN 201910116368 A CN201910116368 A CN 201910116368A CN 109550027 A CN109550027 A CN 109550027A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- concentrate
- parts
- jujube
- ethyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940100688 oral solution Drugs 0.000 title claims abstract description 37
- 230000003860 sleep quality Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 241000208340 Araliaceae Species 0.000 claims abstract description 31
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 31
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 31
- 235000008434 ginseng Nutrition 0.000 claims abstract description 31
- 210000000582 semen Anatomy 0.000 claims abstract description 23
- 241001247821 Ziziphus Species 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
- 235000019441 ethanol Nutrition 0.000 claims description 47
- 239000012141 concentrate Substances 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 13
- 239000011259 mixed solution Substances 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 238000007689 inspection Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 235000021552 granulated sugar Nutrition 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000004064 recycling Methods 0.000 claims 1
- 230000007958 sleep Effects 0.000 abstract description 36
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 11
- 206010022437 insomnia Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 206010033557 Palpitations Diseases 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 4
- 239000010839 body fluid Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 3
- 208000010643 digestive system disease Diseases 0.000 abstract description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000000087 stabilizing effect Effects 0.000 abstract description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 206010059013 Nocturnal emission Diseases 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 210000003462 vein Anatomy 0.000 abstract description 2
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 241000256856 Vespidae Species 0.000 description 12
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 11
- 229960000796 barbital sodium Drugs 0.000 description 9
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 9
- 230000028527 righting reflex Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 230000004620 sleep latency Effects 0.000 description 6
- 206010003084 Areflexia Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000036578 sleeping time Effects 0.000 description 5
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 244000144993 groups of animals Species 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000004622 sleep time Effects 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000005059 dormancy Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 229960001301 amobarbital Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种改善睡眠质量的口服液的制备方法属于保健食品技术领域。本发明以人参、酸枣仁、大枣、益智仁、陈皮为主要原料制备改善睡眠质量的口服液,口服液中人参具有大补元气、生津、养血、宁神、复脉固脱之功效,酸枣仁养心安神,大枣养血安神;益智仁暖肾固精,陈皮燥湿化痰。诸药合用有补气生津、宁心、养血安神之功效,用于体虚、神志不宁、惊悸怔忡、失眠多梦等,适宜于睡眠状况不佳者食用,尤其适合中老年人服用。该口服液适宜需要改善睡眠的人群,并且配方科学、工艺稳定,可以工业化规模生产,具有科学性、可靠性,能丰富改善睡眠类保健食品市场。
Description
技术领域
本发明属于保健食品技术领域,特别是涉及到一种改善睡眠质量的口服液的制备方法。
背景技术
失眠通常指患者对睡眠时间或质量不满足并影响白天社会功能的一种主观体验。据世界卫生组织调查,27%的人有睡眠问题。中国睡眠研究会公布的最新睡眠调查结果,中国成年人失眠发生率为38.2%,高于一些发达国家的失眠发生率。睡眠作为生命所必需的过程,是机体复原、整合和巩固记忆的重要环节,是健康不可缺少的组成部分。医学研究表明,偶尔失眠会造成第二天疲倦和动作不协调,长期失眠则会带来注意力不集中、记忆出现障碍和工作力不从心等后果。此外,失眠与躯体疾病关系密切,睡眠不足会使人免疫力下降,抗病和康复疾病的能力降低,容易感冒,并加重其他疾病或诱发原有疾病的发作,如心血管、脑血管、高血压等疾病。实践还证明,手术后的病人如睡眠不好,伤口愈合的时间会明显延长。儿童如患有严重睡眠不足,会影响其身体发育。
另外,没有健康的睡眠还会产生不少社会问题。随着人类生活水平的提高,人们越来越重视身体的保健。同时,因为生活节奏的加快,社会压力的加大,竞争的日益激烈,越来越多的人处于免疫力低下睡眠不佳的“亚健康”状态。失眠会引起人的疲劳感、不安、全身不适、无精打采、反应迟缓、头痛、记忆力不集中,它的最大影响是精神方面的,严重一点会导致精神分裂和抑郁症。失眠可产生精神萎顿、心悸、头昏眼花、食纳乏味和健忘等并发症,占内科门诊的10%左右。
因此本发明提供一种具有改善睡眠的保健功能,适宜于睡眠状况不佳者食用的口服液制备方法。
发明内容
本发明所要解决的技术问题是:提供一种改善睡眠质量的口服液的制备方法用于睡眠状况不佳者的睡眠质量改善。
一种改善睡眠质量的口服液的制备方法,包括以下步骤,并且以下步骤顺次进行,
步骤一、人参粉碎并用乙醇提取人参浓缩液
称取50份重量份的人参,将人参粉碎成粒径为10目以上的颗粒,用人参重量的10倍量质量浓度50%的乙醇在80℃条件下回流提取两次,每次2小时,将两次提取获得的提取液混合,用100目筛过滤,在-0.02MPa至-0.04MPa减压条件下保持提取液在65℃~75℃回收乙醇并浓缩提取液至与人参的重量相等,获得的液体为人参浓缩液,备用;
步骤二、提取大枣、酸枣仁、益智仁和陈皮的水溶液
按照重量份分别称取大枣150份、酸枣仁150份、益智仁30份和陈皮20份并混合,加水在100℃条件下提取三次,三次加水量依次为大枣、酸枣仁、益智仁和陈皮总重量的6倍、5倍和4倍,提取时间依次为2小时、2小时和1小时,将三次获得的提取液用100目筛过滤后混合,在-0.02MPa至-0.04MPa减压、80℃条件下,浓缩至50℃温度下测量浓缩液的密度为1.06~1.12,放置至室温,获得大枣、酸枣仁、益智仁和陈皮的浓缩液;
步骤三、人参浓缩液与大枣、酸枣仁、益智仁和陈皮浓缩液混合并醇沉
将步骤一获得的人参浓缩液与步骤二中获得的大枣、酸枣仁、益智仁和陈皮的浓缩液混合,搅拌30分钟,用质量浓度95%的乙醇,醇沉至乙醇质量浓度为65%,静置24小时,抽滤,-0.02至-0.04MPa减压、65℃~75℃条件下,回收乙醇并浓缩至50℃温度下测量浓缩液的密度为1.08~1.15,放置至室温;
步骤四、醇沉混合溶液并抽滤
将步骤三中获得的混合溶液用质量浓度95%的乙醇,醇沉至乙醇质量浓度为75%,静置24小时,抽滤,-0.02至-0.04MPa减压、65℃~75℃条件下,回收乙醇并浓缩至50℃温度下测量浓缩液的密度为1.08~1.15,抽滤,获得醇沉后的混合溶液;
步骤五、向步骤四中获得的醇沉后的混合溶液中加入白砂糖和山梨酸钾,加入纯化水至规定容量,搅拌30分钟;
步骤六、灭菌、过滤、灌封,经灯检、贴签、包装、成品检验后即得成品,入库。
所述步骤五中加入的白砂糖为100重量份、山梨酸钾为1重量份。
所述步骤六中的灭菌为100℃条件下灭菌60分钟以上。
通过上述设计方案,本发明可以带来如下有益效果:
失眠多系情志所伤、劳逸失调、病后体虚或饮食不节,以致心脾不足、气血虚少、心神失养,治疗当以补气、养血、安神为原则。本发明是以人参、酸枣仁、大枣、益智仁、陈皮为主要原料制备改善睡眠质量的口服液,口服液中人参具有大补元气、生津、养血、宁神、复脉固脱之功效,酸枣仁养心安神,大枣养血安神;益智仁暖肾固精,陈皮燥湿化痰。诸药合用有补气生津、宁心、养血安神之功效,用于体虚、神志不宁、惊悸怔忡、失眠多梦等,适宜于睡眠状况不佳者食用,尤其适合中老年人服用。该口服液适宜需要改善睡眠的人群,并且配方科学、工艺稳定,可以工业化规模生产,具有科学性、可靠性,能丰富改善睡眠类保健食品市场。
附图说明
以下结合附图和具体实施方式对本发明作进一步的说明:
图1为本发明一种改善睡眠质量的口服液的制备方法的流程框图。
图2为本发明一种改善睡眠质量的口服液的制备方法中实施例的表1。
图3为本发明一种改善睡眠质量的口服液的制备方法中实施例的表2。
图4为本发明一种改善睡眠质量的口服液的制备方法中实施例的表3。
图5为本发明一种改善睡眠质量的口服液的制备方法中实施例的表4。
图6为本发明一种改善睡眠质量的口服液的制备方法中实施例的表5。
图7为本发明一种改善睡眠质量的口服液的制备方法中实施例的表6。
图8为本发明一种改善睡眠质量的口服液的制备方法中实施例的表7。
图9为本发明一种改善睡眠质量的口服液的制备方法中实施例的表8。
图10为本发明一种改善睡眠质量的口服液的制备方法中实施例的表9。
图11为本发明一种改善睡眠质量的口服液的制备方法中实施例的表10。
具体实施方式
如图所示,一种改善睡眠质量的口服液的制备方法,包括以下步骤,并且以下步骤顺次进行,
步骤一、人参粉碎并用乙醇提取人参浓缩液
称取50份重量份的人参,将人参粉碎成粒径为10目以上的颗粒,用人参重量的10倍量质量浓度50%的乙醇在80℃条件下回流提取两次,每次2小时,将两次提取获得的提取液混合,用100目筛过滤,在-0.02MPa至-0.04MPa减压条件下保持提取液在65℃~75℃回收乙醇并浓缩提取液至与人参的重量相等,获得的液体为人参浓缩液,备用;
步骤二、提取大枣、酸枣仁、益智仁和陈皮的水溶液
按照重量份分别称取大枣150份、酸枣仁150份、益智仁30份和陈皮20份并混合,加水在100℃条件下提取三次,三次加水量依次为大枣、酸枣仁、益智仁和陈皮总重量的6倍、5倍和4倍,提取时间依次为2小时、2小时和1小时,将三次获得的提取液用100目筛过滤后混合,在-0.02MPa至-0.04MPa减压、80℃条件下,浓缩至50℃温度下测量浓缩液的相对密度为1.06~1.12,放置至室温,获得大枣、酸枣仁、益智仁和陈皮的浓缩液;
步骤三、人参浓缩液与大枣、酸枣仁、益智仁和陈皮浓缩液混合并醇沉
将步骤一获得的人参浓缩液与步骤二中获得的大枣、酸枣仁、益智仁和陈皮的浓缩液混合,搅拌30分钟,用质量浓度95%的乙醇,醇沉至含醇量为65%,静置24小时,抽滤,-0.02至-0.04MPa减压、65℃~75℃条件下,回收乙醇并浓缩至50℃温度下测量浓缩液的相对密度为1.08~1.15,此时浓缩液已无醇味,放置至室温;
步骤四、醇沉混合溶液并抽滤
将步骤三中获得的混合溶液用质量浓度95%的乙醇,醇沉至含醇量为75%,静置24小时,抽滤,-0.02至-0.04MPa减压、65℃~75℃条件下,回收乙醇并浓缩至50℃温度下测量浓缩液的相对密度为1.08~1.15,此时浓缩液已无醇味,抽滤,获得醇沉后的混合溶液;
步骤五、向步骤四中获得的醇沉后的混合溶液中加入100重量份的白砂糖和1重量份的山梨酸钾,加入纯化水至规定容量,搅拌30分钟;
步骤六、在100℃条件下、灭菌60分钟;将静置后的液体过滤;将滤液灌入洁净口服液瓶中并封盖,10mL/支;经灯检、贴签、包装、成品检验后即得成品,入库。
实施例:
一、改善睡眠动物实验:
1、材料与方法
1.1、样品:由本发明制备的改善睡眠质量的口服液,人体口服推荐剂量为每日30m1,体重按60kg计算,折合剂量0.5m1/kg.bw。采用5倍浓缩液进行试验,折合5倍浓缩液推荐剂量为0.1ml/kg.bw。
1.2、实验动物:SPF级ICR雄性小鼠120只,体重为18g~22g,由湖南斯莱克景达实验动物有限公司提供,实验动物生产许可证号SCXK(湘)2011-0003。饲料由长沙市天勤生物技术有限公司提供。
1.3、实验环境条件:实验环境为屏障环境。实验期间实验环境温度22℃~24℃,湿度54%-58%。实验动物使用许可证号为SYXK(湘)2015-0012。
1.4、剂量选择:将实验动物分成三个实验组,分别记为实验工组(延长戊巴比妥钠睡眠时间实验)、II组(直接睡眠实验和戊巴比妥钠阈下剂量催眠实验)、III组(巴比妥钠睡眠潜伏期实验),每个实验组根据动物体重随机分为四组,每组10只。设本发明制备的口服液5倍浓缩液低、中、高剂量分别为0.5ml/kg.bw、1.0ml/kg.bw、3.0ml/kg.bw(分别相当于人体推荐剂量的5,10,30倍)。试验时,分别取样品5倍浓缩液5.0m1,10.0m1,30.0m1加蒸馏水至200m1,配成低、中、高剂量所需浓度。
每天灌胃一次,灌胃体积为0.2m1/10g.bw,对照组予以等体积的蒸馏水,连续30天后进行指标测定。实验期间动物自由摄食饮水。每天观察动物的活动及生长情况。
1.5、仪器与试剂:AEU210电子天平、电子天平、秒表、戊巴比妥钠、巴比妥钠、生理盐水。
1.6、实验方法:
1.6.1、直接睡眠实验
观察动物给予3个剂量的受试样品,对照组给予同体积溶剂后,是否出现睡眠现象,睡眠以翻正反射消失为指标。当小鼠置于背卧位时,能立即翻正身位,如超过30秒~60秒不能翻正者,即认为翻正反射消失,进入睡眠。翻正反射恢复即为动物觉醒,翻正反射消失至恢复这段时间为动物睡眠时间,记录对照组与受试样品组入睡动物数及睡眠时间。
1.6.2、延长戊巴比妥钠睡眠时间实验
动物末次给予受试物后15min,给各组动物按42mg/kg.bw剂量腹腔注射戊巴比妥钠,注射量为0.1ml/10g.bw,以小鼠翻正反射消失为睡眠指标,观察受试物对戊巴比妥钠睡眠时间的延长作用。
1.6.3、戊巴比妥钠阈下剂量催眠实验
动物末次给予受试物后15min,给各组动物按32mg/kg.bw剂量腹腔注射戊巴比妥钠,注射量为0.1ml/lOg.bw,以小鼠翻正反射消失达1min以上作为入睡判断标准,观察给戊巴比妥钠30min内各组动物发生睡眠的动物数。
1.6.4、巴比妥钠睡眠潜伏期实验
动物末次给予受试物后15min,给各组动物按296mg/kg.bw剂量腹腔注射巴比妥钠,注射量为0.1ml/10g.bw,以翻正反射消失为指标,观察受试样品对巴比妥钠睡眠潜伏期的影响。
1.7、统计分析处理:
用Spss软件进行数据转化和统计分析。用Spss软件统计比较时,先对数据进行方差齐性检验,若方差齐,采用单因素方差分析进行总体比较发现差异再用Dunnett法进行多个剂量组与一个对照组均数间的两两比较。若方差不齐,则对原始数据进行适当的变量转换,满足方差齐性检验后,用转换后的数据进行统计;若变量转换后仍未达到方差齐的目的,改用秩和检验进行统计,发现总体比较有差异,则采用不要求方差齐性的Tamhane'sT2检验进行两两比较。对于计数资料,用x2检验进行比较。
2.结果:
2.1、本发明制备的口服液对动物体重的影响
由图2~图4所示的表1~表3可以看出,各剂量组与对照组比较,实验期间体重均无显著性差异(P>0.05);动物生长良好,未见明显异常反应。表1为本发明制备的口服液改善睡眠(I)组小鼠体重。表2为本发明制备的口服液改善睡眠(Ⅱ)组小鼠体重。表3为本发明制备的口服液改善睡眠(Ⅲ)组小鼠体重。
2.2、直接睡眠实验
由图5所示的表4本发明制备的口服液对小鼠直接睡眠实验的影响可见,各剂量组与对照组,经口灌胃后小鼠不出现睡眠现象。
2.3、延长戊巴比妥钠诱导的小鼠睡眠时间试验
由图6所示的表5本发明制备的口服液对戊巴比妥钠诱导小鼠睡眠时间的影响可见,各剂量组与对照组比较,对戊巴比妥钠诱导的小鼠睡眠时间有延长趋势,经统计学检验,高剂量组与对照组比较差异有显著性(P<0.05)。
2.4戊巴比妥钠阈下剂量催眠试验
由图7所示的表6本发明的口服液对阈下剂量戊巴比妥钠诱导小鼠睡眠发生率的影响可见,各剂量组小鼠睡眠发生率与对照组比较,差异无显著性(P>0.05)。
2.5、巴比妥钠睡眠潜伏期实验
由图8所示的表7本发明制备的口服液对巴比妥钠睡眠潜伏期的影响可见,高剂量组巴比妥钠睡眠潜伏期明显低于对照组,差异有显著性(P<0.05)。
3、小结:
在本实验室条件下,以0.5ml/kg.bw、1.0ml/kg.bw、3.0ml/kg.bw剂量的本发明制备的口服液5倍浓缩液给小鼠灌胃30天,剂量组小鼠体重与对照组比较,差异无显著性(P>0.05)。对受试动物无直接睡眠作用。3.Om1/kg.bw剂量能明显缩短巴比妥钠睡眠潜伏期、延长阈剂量戊巴比妥钠诱导的小鼠睡眠时间,与对照组比较差异有显著性(P<0.05)。对阈下剂量戊巴比妥钠诱导的小鼠睡眠发生率无明显影响。提示本发明制备的口服液具有改善睡眠作用。
二、甜味剂和产品感官考察
白砂糖为本品甜味剂,考察产品的白砂糖用量和口感的关系。由于本品酸枣仁成酸性,所以没有添加酸味剂。设计了1000mL计。配方中原料不变的情况下,根据以上实验结合感官,图9所示的表8不同糖酸比对产品口感影响结果显示配方3最好。
三、灭菌条件
将产品分为三组,按图10所示的表9产品灭菌条件试验结果的三种灭菌条件灭菌。产品灭菌条件试验结果表明,三组灭菌产品都未检测到微生物。考虑到最大限度保留有效成分要求,我们选用100℃灭菌60min。
四、中试试验
本中试1505001批、1505002批按配方量30倍投料,10ml/支,计划每批生产3000支成品。1505003按配方60倍投料,其中取出30L灌封前物料进行浓缩,浓缩至6L用于动物试验。通过3批次中试生产,分别考察了实际得量、成品率等中试生产技术数据,结果证明产品工艺稳定。中试技术数据见图11所示的表10三批中试产品生产验证技术数据。
Claims (3)
1.一种改善睡眠质量的口服液的制备方法,其特征是:包括以下步骤,并且以下步骤顺次进行,
步骤一、人参粉碎并用乙醇提取人参浓缩液
称取50份重量份的人参,将人参粉碎成粒径为10目以上的颗粒,用人参重量的10倍量质量浓度50%的乙醇在80℃条件下回流提取两次,每次2小时,将两次提取获得的提取液混合,用100目筛过滤,在-0.02MPa至-0.04MPa减压条件下保持提取液在65℃~75℃回收乙醇并浓缩提取液至与人参的重量相等,获得的液体为人参浓缩液,备用;
步骤二、提取大枣、酸枣仁、益智仁和陈皮的水溶液
按照重量份分别称取大枣150份、酸枣仁150份、益智仁30份和陈皮20份并混合,加水在100℃条件下提取三次,三次加水量依次为大枣、酸枣仁、益智仁和陈皮总重量的6倍、5倍和4倍,提取时间依次为2小时、2小时和1小时,将三次获得的提取液用100目筛过滤后混合,在-0.02MPa至-0.04MPa减压、80℃条件下,浓缩至50℃温度下测量浓缩液的密度为1.06~1.12,放置至室温,获得大枣、酸枣仁、益智仁和陈皮的浓缩液;
步骤三、人参浓缩液与大枣、酸枣仁、益智仁和陈皮浓缩液混合并醇沉将步骤一获得的人参浓缩液与步骤二中获得的大枣、酸枣仁、益智仁和陈皮的浓缩液混合,搅拌30分钟,用质量浓度95%的乙醇,醇沉至乙醇质量浓度为65%,静置24小时,抽滤,-0.02至-0.04MPa减压、65℃~75℃条件下,回收乙醇并浓缩至50℃温度下测量浓缩液的密度为1.08~1.15,放置至室温;
步骤四、醇沉混合溶液并抽滤
将步骤三中获得的混合溶液用质量浓度95%的乙醇,醇沉至乙醇质量浓度为75%,静置24小时,抽滤,-0.02至-0.04MPa减压、65℃~75℃条件下,回收乙醇并浓缩至50℃温度下测量浓缩液的密度为1.08~1.15,抽滤,获得醇沉后的混合溶液;
步骤五、向步骤四中获得的醇沉后的混合溶液中加入白砂糖和山梨酸钾,加入纯化水至规定容量,搅拌30分钟;
步骤六、灭菌、过滤、灌封,经灯检、贴签、包装、成品检验后即得成品,入库。
2.根据权利要求1所述的一种改善睡眠质量的口服液的制备方法,其特征是:所述步骤五中加入的白砂糖为100重量份、山梨酸钾为1重量份。
3.根据权利要求1所述的一种改善睡眠质量的口服液的制备方法,其特征是:所述步骤六中的灭菌为100℃条件下灭菌60分钟以上。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910116368.7A CN109550027A (zh) | 2019-02-15 | 2019-02-15 | 一种改善睡眠质量的口服液的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910116368.7A CN109550027A (zh) | 2019-02-15 | 2019-02-15 | 一种改善睡眠质量的口服液的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109550027A true CN109550027A (zh) | 2019-04-02 |
Family
ID=65874106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910116368.7A Pending CN109550027A (zh) | 2019-02-15 | 2019-02-15 | 一种改善睡眠质量的口服液的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109550027A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870304A (zh) * | 2021-02-25 | 2021-06-01 | 安徽省芬格欣生物药业有限公司 | 一种可有效助眠的口服液及其制备方法 |
CN114601905A (zh) * | 2022-03-31 | 2022-06-10 | 山东中医药大学 | 一种养血安眠口服液及其制备工艺 |
-
2019
- 2019-02-15 CN CN201910116368.7A patent/CN109550027A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870304A (zh) * | 2021-02-25 | 2021-06-01 | 安徽省芬格欣生物药业有限公司 | 一种可有效助眠的口服液及其制备方法 |
CN114601905A (zh) * | 2022-03-31 | 2022-06-10 | 山东中医药大学 | 一种养血安眠口服液及其制备工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102845749B (zh) | 一种具有改善睡眠和辅助改善记忆功能的保健组合物 | |
CN102907604B (zh) | 一种降糖、降压、减肥、通便养颜、抗疲劳保健品及其生产工艺 | |
CN101926950B (zh) | 一种健脑中药组合物及其制备方法和检测方法 | |
US10893689B2 (en) | Solid beverage for conditioning blood stasis constitution and method for producing the same | |
CN102120015A (zh) | 一种用于舒肝解郁、安神定志的中药及制法和质量标准 | |
CN106723021A (zh) | 一种改善睡眠的功能性食品 | |
CN101637265B (zh) | 一种用于改善睡眠的保健食品 | |
CN101019645B (zh) | 一种缓解疲劳和提高缺氧耐受力的保健食品及其制备方法 | |
CN109550027A (zh) | 一种改善睡眠质量的口服液的制备方法 | |
CN105055855B (zh) | 具有改善睡眠、增强免疫力作用的中药组合物及其制备方法和应用 | |
CN108785412A (zh) | 一种具有改善睡眠功能的组合物及其制备方法 | |
CN107569612A (zh) | 一种改善睡眠的药物及其制备方法 | |
CN101366860B (zh) | 用于利眠袪斑的胶玫口服液 | |
CN101711809A (zh) | 一种治疗产后抑郁症的药物组合物及制备方法和用途 | |
CN100544739C (zh) | 一种增强免疫功能的药物或保健品及其制备方法 | |
CN103735621B (zh) | 一种具有降血脂和增强免疫力作用的中药组合物 | |
CN105267819A (zh) | 一种改善健忘症的保健中药组合物及其制作方法 | |
CN110384793A (zh) | 一种干预阳虚体质的中药组合物、破壁组合物及其制备方法 | |
CN109999088A (zh) | 一种具有润肠通便功效的复方制剂及其应用 | |
CN101461894A (zh) | 一种治疗女性更年期综合症及延缓衰老的药物组合物 | |
CN101623365B (zh) | 白苓健脾颗粒剂及其制备方法 | |
CN105815786A (zh) | 一种双花黄精片剂及其制备方法 | |
CN104435478B (zh) | 用于治疗睡眠障碍的中药组合物、制备方法及用途 | |
CN106177176B (zh) | 一种保健品组合物及其制备方法和用途 | |
CN104189038A (zh) | 用于调理女性生理健康和免疫功能的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190402 |
|
WD01 | Invention patent application deemed withdrawn after publication |